| Bioactivity | Taprenepag (CP-544326) is a potent and selective prostaglandin EP(2) agonist with IC50s of 10 and 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors[1]. | ||||||||||||
| Invitro | Taprenepag (CP-544326) (0.01-1000 nM) increases cAMP levels in HEK293 cells expressing human EP2 (EC50=2.8 nM). Taprenepag has poor corneal permeability in an ex vivo rabbit corneal model[1]. | ||||||||||||
| Name | Taprenepag | ||||||||||||
| CAS | 752187-80-7 | ||||||||||||
| Formula | C24H22N4O5S | ||||||||||||
| Molar Mass | 478.52 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Prasanna G, et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure inpreclinical models of glaucoma. Exp Eye Res. 2011 Sep;93(3):256-64. |
Taprenepag
CAS: 752187-80-7 F: C24H22N4O5S W: 478.52
Taprenepag (CP-544326) is a potent and selective prostaglandin EP(2) agonist with IC50s of 10 and 15 nM for human and ra
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.